# A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers

> **NCT06137703** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 52 (actual)

## Conditions studied

- Biological Availability

## Interventions

- **DRUG:** Zavegepant 100mg non-enteric coated soft gel capsule
- **DRUG:** Zavegepant 100mg immediate release tablet
- **DRUG:** Zavegepant 2 x 100mg immediate release tablets
- **DRUG:** Zavegepant 4 x 25mg enteric coated soft gel capsule

## Key facts

- **NCT ID:** NCT06137703
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-24
- **Primary completion:** 2022-12-07
- **Final completion:** 2022-12-07
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06137703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06137703, "A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06137703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*